^
Association details:
| Biomarker: | SRSF2 P95L |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | CTX-712 (pan-CLK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation
Published date:
11/04/2021
Excerpt:
To further investigate the effect of CTX-712 on tumor growth in vivo, we established 13 MDS/AML-derived xenografts (PDXs), which were treated with varying doses of CTX-712. Among the 13 PDX models, SRSF2 mutation was found in 2 cases, which had the SRSF2 P95H or P95L mutation...Overall, 10 out of 13 PDX AML/MDS models, including 2 SRSF2-mutated models, showed anti-tumor effect of CTX-712.
DOI:
10.1182/blood-2019-131559
